Current and next generation of personalized precision medicine requires individual patient molecular profiling of tumors. Analysis of tumor-linked genetic alterations is increasingly used for diagnostic, prognostic and treatment purposes. However, tissue biopsies are invasive, inconvenient, costly, and potentially dangerous, making them difficult and often, and especially serially, impractical. Liquid Biopsies can overcome the limitations imposed by tissue heterogeneity, less expensive, easy to implement. We are going to develop sensitive metabollomic approaches to analyze circulating tumor cells (CTCs) to aid implementation of liquid biopsy for precision medicine.
Funding: $45K (2022)
Goal: We will optimize the metabolic analysis of CTCs from blood to generate preliminary data for external funding.
Token Investors: Sunitha Nagrath, Deepak Nagrath, Somin Lee
Project ID: 1051